Q1 2024 EPS Estimates for Lantheus Holdings, Inc. (NASDAQ:LNTH) Lowered by Leerink Partnrs

Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) - Research analysts at Leerink Partnrs reduced their Q1 2024 earnings estimates for shares of Lantheus in a research note issued to investors on Wednesday, April 17th. Leerink Partnrs analyst R. Ruiz now expects that the medical equipment provider will post earnings per share of $1.47 for the quarter, down from their prior forecast of $1.48. The consensus estimate for Lantheus' current full-year earnings is $5.72 per share. Leerink Partnrs also issued estimates for Lantheus' Q2 2024 earnings at $1.49 EPS, FY2024 earnings at $5.92 EPS and FY2025 earnings at $5.49 EPS.

Several other equities research analysts have also commented on the stock. B. Riley boosted their price target on shares of Lantheus from $95.00 to $99.00 and gave the company a "buy" rating in a report on Thursday. JMP Securities restated a "market outperform" rating and issued a $100.00 price target on shares of Lantheus in a report on Friday, February 23rd. Truist Financial reaffirmed a "buy" rating and issued a $82.00 price objective (up previously from $80.00) on shares of Lantheus in a research report on Monday, February 26th. Finally, StockNews.com raised shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Saturday, January 13th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $104.71.

Lantheus Stock Up 2.4 %

Shares of NASDAQ:LNTH traded up $1.48 during trading hours on Friday, hitting $63.81. The company's stock had a trading volume of 798,451 shares, compared to its average volume of 1,059,034. Lantheus has a 52 week low of $50.20 and a 52 week high of $100.85. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.80 and a quick ratio of 5.45. The company has a market capitalization of $4.37 billion, a price-to-earnings ratio of 13.75 and a beta of 0.53. The firm's fifty day moving average price is $60.81 and its 200 day moving average price is $62.97.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share for the quarter, beating analysts' consensus estimates of $1.33 by $0.26. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. The company had revenue of $354.00 million during the quarter, compared to analyst estimates of $350.44 million.

Insiders Place Their Bets

In related news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the stock in a transaction on Wednesday, March 6th. The stock was bought at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the purchase, the insider now directly owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of Lantheus stock in a transaction dated Wednesday, March 6th. The shares were acquired at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the transaction, the insider now owns 116,773,394 shares of the company's stock, valued at $110,934,724.30. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Mary Anne Heino sold 93,863 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the sale, the director now directly owns 251,643 shares in the company, valued at approximately $16,434,804.33. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 94,545 shares of company stock worth $6,169,936. Company insiders own 1.50% of the company's stock.

Institutional Trading of Lantheus

Several hedge funds have recently added to or reduced their stakes in LNTH. Tucker Asset Management LLC raised its holdings in Lantheus by 239.0% in the third quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider's stock valued at $28,000 after acquiring an additional 282 shares in the last quarter. Principal Securities Inc. acquired a new stake in Lantheus during the fourth quarter worth approximately $28,000. First Horizon Advisors Inc. raised its holdings in Lantheus by 97.0% during the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider's stock worth $32,000 after purchasing an additional 225 shares in the last quarter. West Tower Group LLC raised its holdings in Lantheus by 534.1% during the fourth quarter. West Tower Group LLC now owns 520 shares of the medical equipment provider's stock worth $32,000 after purchasing an additional 438 shares in the last quarter. Finally, Parkside Financial Bank & Trust raised its holdings in Lantheus by 60.2% during the second quarter. Parkside Financial Bank & Trust now owns 426 shares of the medical equipment provider's stock worth $36,000 after purchasing an additional 160 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.